Biopharma AI

VA’s Nationwide Ambient AI Scribe Rollout: Burnout Buster or Documentation Digitized Trap?

The U.S. Department of Veterans Affairs on March 4, 2026, greenlit ambient scribe AI from Knowtex and Abridge…

ByByAnuja Singh Mar 4, 2026

AI in Clinical Trials: Breakthrough Efficiency or Bottlenecked by Biology’s Chaos?

AI is slashing clinical trial timelines and costs where data flows freely—think 35-50% faster enrollment and 30% OpEx…

ByByAnuja Singh Mar 3, 2026

AI’s R&D Acceleration in Biopharma: Proven Power or Selective Promise?

AI is accelerating biopharma R&D where data abundance meets repeatable decisions—delivering 30-50% timeline compression in target ID and…

ByByAnuja Singh Mar 3, 2026

Agentic AI in Biopharma R&D: From Hype to Hierarchical Autonomy

Agentic AI shifts biopharma R&D from static predictions to dynamic, self-executing agent swarms that plan, act, validate, and…

ByByAnuja Singh Mar 3, 2026
Image Not Found

Is Insilico’s AI Drug Engine “Einstein” Turning China into the Global AI–Pharma Hub?

Insilico Medicine’s AI‑driven drug discovery platform, Pharma.AI “Einstein,” is scaling fast in China, with a major expansion of…

ByByAnuja Singh Mar 4, 2026

China Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?

China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…

ByByAnuja Singh Mar 4, 2026
Scroll to Top